Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1718 - Comprehensive assessment of the feasibility of adoptive cell therapy in colorectal carcinoma


09 Oct 2016


Poster display


Blanca Navarro Rodrigo


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


B. Navarro Rodrigo1, S. Viganò2, P.O. Gannon2, P. Baumgartner2, C. Maisonneuve2, C. Sempoux3, M. Sauvain4, D. Hahnloser4, M. Hubner4, N. Demartines4, L. Kandalaft2, M. Montemurro2, A. Harari2, G. Coukos2

Author affiliations

  • 1 Department Of Oncology, Ludwig Institute for Cancer Research, CHUV/UNIL, 1011 - Lausanne/CH
  • 2 Department Of Oncology, Ludwig Institute for Cancer Research, CHUV/UNIL, Lausanne/CH
  • 3 Institute Of Pathology, CHUV/UNIL, Lausanne/CH
  • 4 Department Of Surgery, CHUV/UNIL, Lausanne/CH


Abstract 1718


Adoptive cell therapy (ACT) can induce objective clinical responses in solid tumors. However, its potential in colorectal cancer (CRC) remains poorly exploited. To this end, several questions need to be addressed: Can tumor-infiltrating lymphocytes (TIL) be isolated from CRC, including cryopreserved samples? Can the contamination by the gut microbiota be circumvented? Are CRC TIL similar to those expanded in melanoma trials?


Cryopreserved samples (n = 10) were obtained from primary colon adenocarcinoma tumors (n = 5) or liver metastasis (n = 5). Dissected fragments (n= 10 - 32) were plated and stimulated with IL-2 (6’000 IU/ml) for 21-28 days (pre-REP). A rapid expansion protocol (REP) consisting of a polyclonal stimulation with PHA was performed in cases where the pre-REP yield was low (< 50 x106 TIL). Microbiological testing (BD BACTECTM) was performed at Day 0 (D0) and was repeated at D14 of the pre-REP after culturing in antibiotic-containing media. Polychromatic flow cytometry analyses were performed at harvest.


Sufficient TIL were successfully obtained from all patients tested. The yield of TIL at harvest was broad, not linked to fragments numbers and ranged from 106 to 109 cells (198 ± 90.9 x106; mean ± SEM). Only 4/10 patients required a secondary REP to reach >50 x106 TIL. Among the primary tumors, the highest potential for TIL isolation was observed for the right-side colon tumors, as opposed to the left side (478 ± 329 x106 vs 5.3 ± 3.8 x106 cells), while no significant difference was observed between primary and metastatic samples. Bacterial contamination was detected at D0 in all primary tumors (and none in metastatic samples; p = 0.02, χ2), but microbiological tests turned negative at D14. Flow cytometry analyses showed that T cells represented 78 ± 6% of the pre-REP TIL with CD4/CD8 ratios ranging from 0.5 to 180 (median 1.62). CD8+ T cells were 74 ± 9.4% effector memory (CCR7CD45RA) and 5.9 ± 2.3% central memory (CCR7+CD45RA), and had an activated phenotype (HLADR+CD25+PD-1+), which is similar to the documented results of melanoma TIL.


Consistent with previous findings in melanoma, we demonstrated the feasibility of TIL expansion in CRC and provide the rationale to move forward with personalized immunotherapy in CRC.

Clinical trial identification

Legal entity responsible for the study

Centre de Therapies expérimentales. CHUV/UNIL


Centre de Therapies expérimentales. CHUV/UNIL - This Research Project was supported by ESMO with the aid of a grant from Amgen. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or Amgen.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings